UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4

FORM 4

 or Form 5 obligations may continu 	ue. See Instructio	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									<u> </u>	nouro per reo	ponoc.	0.0			
1. Name and Address of Reporting Person" <u>Conterno Enrique A</u>						2. Issuer Name and Ticker or Trading Symbol <u>LILLY ELI & CO</u> [LLY]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			
(Last) (First) (Middle) LILLY CORPORATE CENTER					3. Date of Earliest Transaction (Month/Day/Year) 01/27/2017									X Officer (give title below) Other (specify below) Sr. VP & Pres., Lilly Diabetes			
(Street) INDIANAPOLIS IN 46285 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individu X	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3)					2. Transact Date (Month/Day	Exec	Execution Date,		3. Transaction Code (Instr. 8) 4. Secu 3, 4 and		rities Acquired (A) or Disposed Of (E d 5)			5. Amount of Securiti Beneficially Owned F Reported Transactior	ollowing Direct (D	. Ownership Form: irect (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr.
					(Month/Day		(Month/Day/Year)	Code \	v I	Amount		(A) or (D)		(Instr. 3 and 4)	i(s) (ir	(1150.4)	4)
Common Stock						017		Α		20),211	Α	\$75.38	133,783		D	
Common Stock														4,926		Ι	401(k)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac (Instr. 8)	tion Code	5. Number o Securities A Disposed of and 5)	f Derivative cquired (A) or (D) (Instr. 3, 4	Expiration	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Derivative Security (Instr. 3 and 4		ities Underlying and 4)	Underlying B. Price of Derivative Security (Instr. 5)		of 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisab		piration te	Title		Amount or Number of Shar	es	Reported Transaction(s) (Instr. 4)	n(s)	
Restricted Stock Unit	(1)	01/27/2017		A		21,326		02/01/201	18 02	/01/2018	Comm	on Stock	21,326	\$0	21,326	D	

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.

Remarks:

<u>Tiffany R. Benjamin for Enrique Conterno,</u> <u>authorization on file</u> ** Signature of Reporting Person

01/31/2017 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Refinite: Report of a separate file to each class of securities beneficially owned includy of indirectly.
 If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
 Intentional misstatements or omissions of facts constitute Federal Criminal Volations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
 Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Enrique A. Conterno Lilly Corporate Center Indianapolis, Indiana 46285

Securities and Exchange Commission Washington, D.C. 20549

AuthorizationRegardingReportingForms

I hereby authorize and designate the following persons to sign and file with the Commission on my behalf Forms 3, 4, and 5 (including any amendments thereto) coverir Michael J. Harrington, Lilly Corporate Center, Indianapolis, Indiana

Bronwen L. Mantlo, Lilly Corporate Center, Indianapolis, Indiana

Tiffany R. Benjamin, Lilly Corporate Center, Indianapolis, Indiana

This authorization and designation shall remain in effect until a written revocation is signed by me and provided to the Commission.

Date: July 25, 2016

/s/ Enrique A. Conterno